Hormonal therapy has been mainstay of treatment for advanced forms of prostate cancer for over 50 y. The choice of hormonal therapy for carcinoma of the prostate depends not only on the desired progression-free and overall survival but also on the patient's quality of life, treatment costs and treatment toxicities. At the present time, several important questions have been raised over optimal treatment modalities for advanced prostate cancer. The optimal form of this therapy is still an enigma.
Introduction
Prostate cancer is the most frequently diagnosed male neoplasm and the second leading cause of cancer death among American men. It was estimated that 41 800 men would die from this disease in the United States in 1997. 1 Despite the efforts of screening and early diagnosis of prostate cancer in recent years, a large proportion of these patients, with localized disease, progress. 2Y 3 The concept of advanced prostate cancer is changing since the majority of patients with advanced disease now present with rising prostate speci®c antigen (PSA) following de®nitive therapy. The classic presentation of advanced disease in which patients ®rst presented by distant bony metastasis or soft tissue involvement is now decreasing. Currently, the de®nition of advanced prostate cancer must include not only soft tissue or bony metastasis (D2) but also stage D0, Dl (N ), C (T3), a rising PSA after de®nitive therapy, and an initial high Gleason grade (9/10) . 4 A new spectrum was suggested for stage D prostate cancer by Crawford 5 which outlines a new stage D 2.5 that presents with rising PSA after nadir.
The controversial issues of timing, duration and long term side effects of androgen deprivation are the main focus of this article. This review will also discuss some of the current challenges in the hormonal management of advanced prostate cancer.
Historical background
The landmark observation of Huggins and Hodges in 1941 6 established androgen deprivation therapy as the ®rst line of treatment for advanced prostate cancer. This was the basis of orchiectomy and estrogen therapy for palliation of prostate cancer. The results of the ®rst clinical series of patients treated wit prostatectomy was published one year 1ater. 7 Despite the good initial response, progression was observed in most patients. This observation led to consideration of a possible role of adrenal gland androgens. Huggins and Scott 8 performed bilateral adrenalectomy in patients exhibiting progression after castration, but the procedure was abandoned because of adrenal insuf®ciency. Bilateral orchiectomy and medical castration with estrogen was the gold standard for the treatment of advanced prostatic cancer until 1967. The cardiovascular side effects of estrogen therapy were later reported by the Veterans Administrative Cooperative Urological Research Group (VACURG) study. 9 Geller, 10 in 1978, proved the importance of adrenal androgens, and postulated that dihydrotestosterone (DHT) was important for androgenic stimulation of prostate cancer. Bracci 11 reported that orchiectomy combined with cyproterone acetate (CPA) had increased success in the treatment of advanced prostate cancer. These ®ndings promoted the search for novel therapy modalities of prostate cancer. Figure 1 shows the in¯uence of the hypothalamus, pituitary, adrenal and testicular hormones at the prostate cellular level. Luteinizing hormone releasing hormone (LHRH) agonists were developed for medical castration; 12 and antiandrogens were synthesized to block the androgenic effect peripherally in patients with advanced prostatic cancer. As a result of these ®ndings, the concept of combined androgen blockade was described by Labrie. 13 He noted a signi®cant improvement in response and survival rate when combining an LHRH agonist with an antiandrogen.
Rationale for combined androgen blockade
The rationale for CAB is based on Labrie's hypothesis 13 regarding mixed cell populations with a wide range of phenotypes in advanced tumors. According to this theory, the androgen-dependent cells contained within the tumor have different requirements of androgen for maintaining function and growth. Conventional monotherapy with either orchiectomy or LHRH agonist only achieves ablation of testicular androgens. Suppression and destruction of the prostate cancer cells with high or moderate androgen dependence may occur initially, resulting in a response to therapy. However, the cells with low androgen requirements will be maintained by androgens of adrenal origin. This population of cells continues to grow and later evolve into androgen-independent cells.
The objective of combination therapy is to block all androgens from testicular and adrenal origin and hence prevent overgrowth of all androgen sensitive cells. Blocking the effect of androgens is achieved by lowering levels of circulating hormone as well as by blocking the receptor site. As a result, the interaction of dihydrotestosterone (DHT) and testosterone with the receptor is prevented. Eliminating testicular androgens, either by orchiectomy or LHRH agonist, will reduce DHT within the prostate by 60%. As adrenal androgens account for 40% of DHT within the prostate, the value of combining an anti-androgen with orchiectomy or an LHRH agonist should be evident. The ideal anti-androgen should have high speci®city and af®-nity for the receptor and should not have intrinsic activity. The ideal anti-androgen has not yet been developed.
Hormonal therapy options Bilateral orchiectomy
This procedure has been the gold standard therapy to which others are compared. It is the least costly, relatively well tolerated and does not have life-threatening complications. Side effects include surgical trauma, decreasing libido, impotence, hot¯ushes, and weight gain. Irreversibility is the most important disadvantage. Subcapsular orchiectomy has overcome the cosmetic disadvantage but may not be acceptable among younger patients. To avoid the higher cost and inconvenience of frequent depot injections of an LHRH agonist, orchiectomy is a valid alternative. 14 
Estrogen therapy
In 1940, this nonsurgical form of castration was introduced. 15 The principle is to inhibit the release of LHRH from the hypothalamus. Diethylstilbestrol (DES) has been shown to have direct cytotoxic effects that theoretically may make it more effective than other agents. 12 À 18 VACURG studies demonstrated the ef®cacy and toxicity of DES in treatment of prostate cancer. 9, 19 These studies reported that DES 1 mg/d is as effective as 5 mg/d for therapy of advanced prostate cancer but not consistent. 20 Estrogen therapy is associated with serious toxicity that includes nausea, vomiting, gynecomastia as well as increased risk of cardiovascular and thromboembolic complications such as deep vein thrombophelibitis, pulmonary embolism, heart attack and sometimes death. 19Y 30 Taking a`baby aspirin' daily can minimize these side effects or toxicity, but there are no studies to support this proposal. 14, 22 Data demonstrate that DES is still prescribed in about 3% of advanced prostate cancer cases. 23 Although, DES is at least as effective as other forms of monotherapy for advanced prostate cancer, it is no longer available in many countries.
LHRH agonist
LHRH analogues came into use in the 1980s and provided a medical form of castration for treatment of advanced prostate carcinoma. 12 Many studies have determined them to be as effective as DES and bilateral orchiectomy without serious side effects. 12, 24, 25 Another advantage of these agents over surgical castration is reversibility. LHRH agonist therapy has become the more acceptable method of castration. However, the effects of LHRH agonists are limited only to the blockade of testicular androgens. Therefore, it should not be expected to decrease the levels of dehydroepiandrosterone (DHEA), dehydroepiandrosterone-sulfate (DHEA-S) by the adrenals. Disadvantages of LHRH agonists still remain the very expensive cost as well as an initial¯aring of symptoms. Combined androgen blockade for advanced prostatic carcinoma S Goktas et al
Flare phenomenon
Initially, the administration of a LHRH agonist causes a stimulation of LH and FSH release with a increase in the hormone production from the testes before testosterone production is shut down. Waxman 26 demonstrated that another possible reason for this`¯are' phenomenon could be a direct stimulation of the malignant cells that contained GnRH receptors. This sudden increase in the level of circulation androgens may cause serious side effects such as paralysis from pathological fractures due to spinal bone metastases and acute urinary retention. Combination therapy with an antiandrogen initially is often prescribed to prevent such side effects. The anti-¯are effect of Cyproterone Acetate (CPA) has been described when used at the dose of 100 mg/d for four weeks before the initiation of LHRH agonist therapy. 27 Additionally pretreatment with two weeks of¯utamide has been shown to have anti¯are effect. 28 
LHRH antagonist
A newer form of this therapy is the LHRH antagonist. These agents are direct antagonists of the LHRH receptor and immediately suppress androgen production hence avoiding the¯are phenomenon associated with LHRH agonists. Early use of LHRH antagonists was associated with releasing histamine, and these agents brought about anaphylactic reactions. LHRH antagonists are still in clinical trials.
Antiandrogens
In the last 20 y, several antiandrogens have been developed for the treatment of prostate cancer. Currently, four orally active antiandrogenic agent available: cyproterone acetate (CPA),¯utamide, nilutamide, and bicalutamide. Steroidal antiandrogens such as CPA have progesteronelike effects. These effects cause a decrease in the releasing of LH by the hypophysis, thus production and activity of testosterone is decreased. The nonsteroidal antiandrogens (¯utamide, nilutamide, and bicalutamide) block the binding of androgens to the receptor not only in the prostate but also in the hypothalamic-pituitary axis. As a result, serum testosterone is increased. Furthermore, because serum androgen levels remain high, many men remain potent. Nonsteroidal antiandrogens have minimal side effects. The most common side effects are breast tenderness and breast swelling which occurs as a result of stimulating LH release and increased serum testosterone, some of which is aromatized to estrogen. However, these agents as monotherapy have never shown bene®t to survival when compared to surgical castration for treatment of advanced prostate cancer. 29, 30 Antiandrogens are not accepted as monotherapy as standard care. Their indication is in combination with either orchiectomy or with a LHRH for combined androgen blockade. Flutamide or other pure antiandrogens may be useful for sexually active patients who wish to remain potent. Libido and sexual potency are preserved in 80±100% of patients treated with this drug. 31 À 33 Antiandrogen monotherapy may play a role in selected indications which include T4 disease with minimal distant metastasis, T3 patients who are not candidates for either surgery or radiotherapy, adjuvant to radical prostatectomy for patients at high risk (margin positive, Gleason b 7, high initial PSA), early prostate cancer (Tlc-T2) in patients above 70 y or sexual priority for the patient.
Cyproterone acetate (CPA)
The steroidal antiandrogen CPA has been widely used in European countries for the treatment of advanced prostate cancer since 1966. 34 Brachi 11 and Varenhorst 35 determined that CPA at 200 g/d dose produces a regression of prostate tumor similar to the effect of castration. However, it caused considerable change in libido and sexual potency; a diminished libido and impotence was reported in 86% of treated patients. 36 There are no side effects in the ability to concentrate, lethargy or hot¯ushes as which occurs after orchiectomy or medical castration with LHRH alone. As mentioned above, it has shown to have an anti-¯are effect at dose 100 mg/d. 27 
Flutamide
This was the ®rst pure antiandrogen to be developed. Flutamide has been shown to have hormonal activity only on androgen-dependent sex structures. 37, 38 Flutamide monotherapy was shown to reduce bone pain in 77% with minimal change in libido or sexual potency in patients with previously untreated advanced prostate cancer. 31 Other investigators 31, 32, 39 con®rmed the ef®cacy of¯utamide. Additionally, pretreatment with two weeks of¯utamide has been shown to block the testosteronē are. 28 All of these studies found side effects of¯utamide monotherapy including hepatic and gastrointestinal disturbances such as nausea, anorexia, and diarrhea which leads to discontinuing of therapy in 10±20% of patients.
Nilutamide
Nilutamide differs from¯utamide in its lateral chain. This change prolongs its half-life and therefore the drug can be recommended in one daily 150 mg dose. The publications regarding the clinical use of nilutamide as a monotherapy are limited. The effect of nilutamide in untreated advanced prostatic carcinoma patients was studied showing mean progression-free survival and overall survival to be 9 and 23 months, respectively 40 Approximately onethird of the patients complained of visual disturbance such as diminished adaptation to darkness.
Bicalutamide
The latest nonsteroidal antiandrogen. It has a long halflife and can be given in single daily dosing. Newling 41 reported that the overall objective response rate of bicalutamide treatment is 50% in previously untreated advanced prostate cancer cases. The most common side effect in this study was breast tenderness that occurred in about 50% of patients. In Tyrrell's studies 30 the partial response rate was reported as 55.5%. Common side effects were breast swelling (52.5%) and breast tenderness (63.4%). Additionally, this study determined that the dosage can be increased to 200 mg/d and tolerability remains good. Bicalutamide therapy also does not cause gastrointestinal disturbances and diminished dark adaptation. Hepatic toxicity has been reported. Dose ®nding studies are ongoing and doses up to 600 mg are being evaluated.
Combined androgen blockade (CAB)
Combined androgen blockade is based on the premise of eliminating simultaneously all sources of androgens, those produced from the testes by using medical (LHRH agonist) or surgical castration (bilateral orchiectomy) and those arising from the adrenal glands by the use of an antiandrogen. The theory of CAB results from the hypothesis advocated by Labrie et al. 13 Labrie et al, 13, 42 reported a 96% response rate with 29.2% complete response rate and long-term survival in 37 patients with advanced prostate cancer who were treated with the combined androgen blockade. However, this non-randomized study included no control arm.
Several studies have been completed that used surgical castration with an antiandrogen as a modality for CAB. Two major randomized studies, the SWOG-INT. 0036, 43 EORTC 3085 44 documented the superiority of CAB. Other well-designed clinical trials con®rmed the superiority of this approach to bilateral orchiectomy or LHRH agonist monotherapy. 45 Others however have not revealed any survival advantage 46±49 As a result, the controversy surrounding CAB could not resolved.
Clinical trials of combined androgen blockade
Clinical studies that support the survival bene®ts of CAB The National Cancer Institute conducted a pivotal intergroup study which randomized 603 patients with advanced prostate cancer and compared l mg daily leuprolide with or without 750 mg daily¯utamide. 43 This was the ®rst randomized trial that showed a progression and survival bene®t of CAB. The study involved 300 patients receiving leuprolide and placebo versus 303 patients randomly assigned to receive leuprolide and¯utamide. The combination therapy group had a longer progression-free survival (16.5 vs 13.9 months; P 9.039) and an increase in the median length of survival (35.6 vs 28.3 months; P 0.035). The differences between the treatments were particularly evident for men with minimal disease and good performance status. Symptomatic improvement was greatest during the ®rst 12 weeks of the combined androgen blockade, when leuprolide alone often produces a painful¯are in the disease. The study demonstrated that in patients with advanced prostate cancer, treatment with leuprolide and¯utamide is superior to treatment with leuprolide alone. The other landmark study that supported CAB was EORTC-30853 which compared goserelin acetate plus¯u tamide with bilateral orchiectomy. 44 This study showed approximately seven months survival advantage in the CAB group. Both improvement in time to progression and overall survival were achieved in the combined arm. In patients with minimal metastatic disease, this improvement was more apparent. The Anandron Study Group 45 compared bilateral orchiectomy and placebo with bilateral orchiectomy and nilutamide in a multinational double-blind investigation involving 457 patients with advanced prostate cancer. Patients receiving bilateral orchiectomy and nilutamide had a 7.3 months survival advantage and time to progression was extended from 14.9±20.9 months. Recently Dijkman et al 50 reported that at 8.5 y follow-up signi®cant bene®ts were found for progression-free survival (21.2 months vs 14.7 months) and cancer speci®c survival (37 months vs 29.8 months) in favor of patients receiving Nilutamide and orchiectomy.
Clinical studies that do not support the survival bene®ts of CAB
The EORTC open, multicenter, three-armed, randomized study that could not show any signi®cant bene®cial effect of CAB compared to medical or surgical castration alone in terms of response rate, time-toprogression, overall survival and cancer deaths. 46 The PONCAP study 47 randomized patients with stage T3 and M prostate cancer and compared medical castration (with goserelin acetate) with or without utamide. No signi®cant differences among the two treatment arms with respect to survival time and timeto-progression were observed. The International Prostate Cancer Study included 589 patients with advanced prostate cancer, comparing patients receiving monthly goserelin alone to those receiving goserelin plus¯utamide. There were no differences either in time-to-progression or survival time. 48 The Danish Prostatic Cancer Group (DAPROCA) is another study that compared gosereline acetate plus utamide with orchiectomy in 264 previously untreated advanced prostate cancer patients. With a median follow-up of 57 months, no signi®cant differences were found between treatment arms with regard to progression free survival and overall survival. 49 The NCI 0105 study (combined SWOG and ECOG), recently reported by Crawford et al, 51 comparing progression free-survival and overall survival in patients receiving bilateral orchiectomy plus/minus¯utamide 250 mg TID. This study failed to show a statistical bene®t to adding¯utamide to bilateral orchiectomy although there was a three months survival advantage. The only signi®cant difference between the two groups were the greater rates of diarrhea and anemia with utamide.
Meta-analysis of CAB
The ®rst meta-analysis included data from seven randomized, double-blind studies. 52 The study compared orchiectomy plus nilutamide with orchiectomy plus placebo Combined androgen blockade for advanced prostatic carcinoma S Goktas et al on 1056 patients with advanced prostate cancer. The group receiving CAB had a signi®cant reduction in terms of disease progression. There was also a reduction of 10% in the risk of death but was not signi®cant statistically. Other meta-analyses have determined a slight survival to CAB. 53 The Prostate Cancer Trialists' Collaborative Group 54 recently published a meta-analysis which included 22 trials and a total of 5710 patients with advanced prostate cancer of which 3283 (57%) had died. Some trials used medical castration (with three different LHRH agonists: leuprolide, goserelin, and buserelin) and some used bilateral orchiectomy as part of CAB. Median follow-up was 40 months. Overall, mortality was 56.3% in those receiving CAB compared with 58.4% in those receiving medical or surgical castration alone. Five-year survival estimates were 26.2% with CAB and 22.8% with castration alone (95% CI: 0±7%). The CAB group had 6.4% reduction in the annual odds of deaths but again this was not signi®cant statistically. Thus, the meta-analysis of 22 published studies suggests no statistically signi®cant survival advantage to CAB. Even if surgical or medical castration alone is attractive with regard to minimizing morbidity and cost, current data cannot prove its equivalence or superiority to CAB.
Anti-androgen withdrawal syndrome
This syndrome was ®rst reported by Kelly and Scher 55 in 1993 in prostate cancer patients treated with an LHRH agonist and¯utamide. 10 of 27 patients who were treated with CAB and subsequently stopped¯utamide during time of disease progression experienced signi®cant remission and PSA decline which continued for an average of ®ve months. This syndrome has also been observed with other pure and steroidal antiandrogens, 56,57 megestrol acetate, 58 , and DES 59 The mechanism of this syndrome is not fully understood. Several hypotheses have been offered to explain this syndrome; but, clinically, none has yet been con®rmed in patients with treated antiandrogen monotherapy.
Optimal timing and duration of therapy
The timing and duration of treatment have been hotly debated issues. Hormonal therapy for advanced prostate cancer causes a temporarily response, and relapse occurs usually within two years. 60 Optimal timing and duration of hormonal therapy is affected by the cost burden of treatment.
Early or deferred
The timing of hormonal deprivation therapy for asymptomatic patients remains a challenge. 61, 62 The concept of deferred hormonal therapy in asymptomatic advanced prostate cancer patients was largely based on VACURG studies 18 which showed that survival not prolonged by early hormonal therapy. However, an update by Byar in 1988 of the VACURG study 62 determined that patients with untreated stage C disease show progression to stage D disease with a 30% rate within 24 months and 50% within 52 months. The other result from these studies was that disease progression from stage C to stage D was decreased from 50±10% with DES therapy. Crawford and colleagues supported a bene®cial effect of early androgen suppression men who have good performance status and few bone metastases. 43, 63 Results from EORTC trial 30846 suggested the superiority of an immediate treatment approach. 53 The MRC study was the ®rst large randomized study of 938 patients with locally advanced or asymptomatic metastatic prostate cancer. 64 Half of the patients received immediate treatment with orchiectomy or LHRH agonist. The remaining patients received same treatment but deferred until symptoms occurred. The results of this pivotal study strikingly favored immediate therapy. Progression from M0 disease to M1 disease (P`0.001) and development of metastatic pain occurred more rapidly in patients receiving deferred treatment. Development of extra-skeletal metastases, pathologic bone fracture, spinal cord compression and ureteric obstruction were approximately twice as common in the deferred therapy patients. The necessity of transurethral resection was observed in 141 deferred patients compared to 65 patients treated early. Overall survival was signi®cantly longer in patients treated immediately, and the difference was also more evident for deaths from prostate cancer.
Currently, there are categorical studies to decide when to treat asymptomatic patients with hormonal therapy. Early androgen suppression will delay the start of disease progression in most treated patients. Thus, the symptomfree interval will lengthen and improve quality of life. 61, 64, 65 This raises the question of intermittent androgen blockade. In spite of a physiopathologic rationale, the original implementation of this therapy was devised by patients who suspended their therapy in an effort to reduce the side effects of combined androgen blockade. Laboratory studies have shown that hormonal independent cancer can be delayed using this approach. 66 Clinicians following these patients noted a sustained biochemical response. 67 Additionally, when the patients PSA began to rise, restarting hormonal therapy was able to reduce PSA levels again. This form of therapy has become very popular despite the fact that there is no long term data to support that it is as safe as continuous therapy. Goldenberg et al 68 reported that patients during the off-treatment period had an improved sense of well being and near normal sexual function. The same study also reported that survival was not compromised. SWOG is currently studying this concept in a large randomized study. The controversy which surrounds intermittent therapy is how long should treatment be stopped and when should it be resumed? In the future, when trials of intermittent therapy with CAB are completed, they might offer a more cost-effective treatment with improved quality of life.
Quality of life and patient choice
The choice of treatment for advanced prostate cancer must also consider issues of patients' acceptance and quality of life. Patients who underwent immediate endocrine therapy were compared with patients who did not receive any therapy at Memorial Sloan-Kettering Cancer Center by assessing quality of life before therapy and six months later showing a bene®t for the no-therapy group. 69 Sexual function was a major factor in the patients' decision to defer immediate treatment. Singer also determined that 68% of patients may be willing to preserve their sexual function for a 10% reduction in 5 y survival. 70 The choice for treatment of advanced prostate cancer was reported from a multicenter study in which 78% selected a LHRH agonist and 22% selected orchiectomy. The primary reasons for choosing the LHRH agonist included the avoidance of surgery (36%), success of treatment (18%), and convenience of the drug (10%). For those who selected surgery, the primary reasons were convenience (32%) and success of treatment (29%). Three months later, 93% of the patients and 91% of patients' wives reported that they would prefer to have the same treatment again. 71 
Cost
The annual healthcare costs for the treatment of patients with prostate cancer were estimated to be $4.5 billion in the United States. 72 This cost is largely related to the treatment of advanced prostate cancer. The Health Care Financing Administration spent $328 million alone for LHRH agonist therapy in 1993. 22 Hillner et al 73 suggested that CAB with¯utamide was more cost-effective than leuprolide alone. The cost estimate for various choices of endocrine therapy for prostate cancer is showed in Table  2 . Although DES probably is as effective and less expensive than a LHRH agonist, it has cardiovascular and thromboembolic complications. This data showed that the addition of¯utamide to the castration adds about $3427.2/year to cost of treatment for a patient with advanced prostate cancer. Orchiectomy also remains an attractive treatment alternative for patients with advanced prostate cancer in regard to cost, ef®cacy, convenience and safety.
Conclusions
The choice of optimal hormonal therapy for carcinoma of the prostate depends not only on the desired progressionfree and overall survival but also on the patient's quality of life, costs of the treatment and treatment toxicities. Although hormonal treatment of advanced prostate cancer remains non-curative, several studies have shown CAB to lengthen progression-free and overall survival in patient groups that may represent the norm today. Additionally, hormonal therapy in patients with advanced prostate cancer does decreases certain complications associated with local tumor progression and other signs and symptoms thus having a positive impact on the quality of life. Combined androgen blockade for advanced prostatic carcinoma S Goktas et al 177
